1. Home
  2. LILAK vs NBTX Comparison

LILAK vs NBTX Comparison

Compare LILAK & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Liberty Latin America Ltd. Class C

LILAK

Liberty Latin America Ltd. Class C

N/A

Current Price

$9.81

Market Cap

1.7B

ML Signal

N/A

Logo Nanobiotix S.A.

NBTX

Nanobiotix S.A.

N/A

Current Price

$30.88

Market Cap

1.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LILAK
NBTX
Founded
2017
2003
Country
Bermuda
France
Employees
N/A
N/A
Industry
Cable & Other Pay Television Services
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.7B
IPO Year
2017
2018

Fundamental Metrics

Financial Performance
Metric
LILAK
NBTX
Price
$9.81
$30.88
Analyst Decision
Hold
Strong Buy
Analyst Count
2
5
Target Price
$8.20
★ $54.24
AVG Volume (30 Days)
★ 1.7M
140.4K
Earning Date
11-04-2026
09-24-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 7.55
N/A
EPS
N/A
★ N/A
Revenue
★ $4,442,200,000.00
N/A
Revenue This Year
$0.60
N/A
Revenue Next Year
$3.23
$50.69
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$4.75
$19.14
52 Week High
$10.42
$57.14

Technical Indicators

Market Signals
Indicator
LILAK
NBTX
Relative Strength Index (RSI) 67.41 51.82
Support Level $7.44 $30.73
Resistance Level N/A $35.17
Average True Range (ATR) 0.48 1.95
MACD 0.18 0.35
Stochastic Oscillator 76.79 46.22

Price Performance

Historical Comparison
LILAK
NBTX

About LILAK Liberty Latin America Ltd. Class C

Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.

About NBTX Nanobiotix S.A.

Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.

Share on Social Networks: